FDA clears echo microbubble contrast agent

Evan Godt | | Health Imaging | Echocardiography

The FDA has approved Lumason, the microbubble contrast agent marketed by Bracco Diagnostics.

Lumason enables contrast-enhanced echocardiographic imaging and uses gas-filled microbubbles to reflect sound waves to enhance an image.

 “Sometimes echocardiograms in certain patients are difficult for physicians to see and interpret,” Libero Marzella, MD, PhD, director of the Division of Medical Imaging Products in the FDA’s Center for Drug Evaluation and Research, said in a release. “Today’s approval provides doctors with another option when performing contrast-enhanced ultrasound.”

Lumason will carry a boxed warning about the risk of serious cardiopulmonary reactions, including fatal cardiac or respiratory arrest. These risks may be increased in those with certain heart conditions.

Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Related Content

FDA clears AI screening tool for cardiac amyloidosis
FDA approves AI startup’s new software for echo assessments
Ultrafast myocardial contrast echocardiography shows early potential to evaluate CAD
ASE establishes vocabulary for cardiac POCUS to promote consistency
Cardiac PET on the rise among U.S. cardiologists
ASE shares new guideline on imaging patients with implanted devices

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.